(BBP) Virtus LifeSci Biotech - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US26923G2021 • Health
BBP: Drugs, Therapies, Pharmaceuticals, Medicines, Vaccines, Biotechnology
Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing. ‣ Company URL: http://www.virtus.com ‣ Domicile: United States
Additional Sources for BBP ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BBP ETF Overview
| Market Cap in USD | 21m |
| Category | Health |
| TER | 0.79% |
| IPO / Inception | 2014-12-16 |
BBP ETF Ratings
| Growth 5y | 47.2% |
| Fundamental | - |
| Dividend | 0.30% |
| Rel. Strength Industry | -72.8 |
| Analysts | - |
| Fair Price Momentum | 57.47 USD |
| Fair Price DCF | - |
BBP Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | 0.00% |
| Payout Consistency | 1.0% |
BBP Growth Ratios
| Growth Correlation 3m | -64.3% |
| Growth Correlation 12m | 67.4% |
| Growth Correlation 5y | 58.8% |
| CAGR 5y | 8.39% |
| CAGR/Mean DD 5y | 0.60 |
| Sharpe Ratio 12m | 0.18 |
| Alpha | -16.29 |
| Beta | 0.81 |
| Volatility | 24.87% |
| Current Volume | 0.3k |
| Average Volume 20d | 1.6k |
What is the price of BBP stocks?
As of January 23, 2025, the stock is trading at USD 61.94 with a total of 296 shares traded.
Over the past week, the price has changed by +3.56%, over one month by +2.39%, over three months by -2.30% and over the past year by +7.35%.
As of January 23, 2025, the stock is trading at USD 61.94 with a total of 296 shares traded.
Over the past week, the price has changed by +3.56%, over one month by +2.39%, over three months by -2.30% and over the past year by +7.35%.
Is Virtus LifeSci Biotech a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Virtus LifeSci Biotech (NYSE ARCA:BBP) is currently (January 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 47.22 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBP as of January 2025 is 57.47. This means that BBP is currently overvalued and has a potential downside of -7.22%.
Partly, yes. Based on ValueRay Analyses, Virtus LifeSci Biotech (NYSE ARCA:BBP) is currently (January 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 47.22 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BBP as of January 2025 is 57.47. This means that BBP is currently overvalued and has a potential downside of -7.22%.
Is BBP a buy, sell or hold?
Virtus LifeSci Biotech has no consensus analysts rating.
Virtus LifeSci Biotech has no consensus analysts rating.
What are the forecast for BBP stock price target?
According to ValueRays Forecast Model, BBP Virtus LifeSci Biotech will be worth about 63.5 in January 2026. The stock is currently trading at 61.94. This means that the stock has a potential upside of +2.52%.
According to ValueRays Forecast Model, BBP Virtus LifeSci Biotech will be worth about 63.5 in January 2026. The stock is currently trading at 61.94. This means that the stock has a potential upside of +2.52%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 63.5 | 2.5% |